EGFR and non-small cell lung carcinoma: In addition, a randomized phase II trial comparing lazertinib, as a third-generation EGFR-TKI, plus LAT to lazertinib alone for patients with synchronous oligometastatic EGFR-mutated NSCLC has been ongoing (NCT05167851).